If Richard Dawkins had been smacked around the head with the double-slit experiment at an age when his skull was soft enough for him to feel the pain, he wouldn't be suffused with such luminous certainty about how the world works.

Evolution, the fundamental theory of biology, is tough for some folk to swallow. But that’s because a bunch of old bearded guys wrote something different a long time ago – and because the intuitions of an animal that lives for 70 years can’t handle what complex systems can get up to in 4.5 billion.

But unlike quantum theory, evolution has nothing mind-warpingly weird about it. So the nature of the real world seems obvious to an evolutionary biologist.

Based on three years of observations from the SCIAMACHY instrument aboard ESA's Envisat, scientists have produced the first movies showing the global distribution of the most important greenhouse gases – carbon dioxide and methane – that contribute to global warming.

The importance of cutting emissions from these 'anthropogenic', or manmade, gases has been highlighted recently with European Union leaders endorsing binding targets to cut greenhouse gases by at least 20 percent from 1990 levels by 2020. Further illustrating the urgency to combat global warming, Britain became the first country last week to propose legislation for cutting the gases.

Using lasers and tuning forks, researchers at Pacific Northwest National Laboratory have developed a chemical weapon agent sensing technique that promises to meet or exceed current and emerging defense and homeland security chemical detection requirements. The technique, called Quartz Laser Photo-Acoustic Sensing, or "QPAS," is now ready for prototyping and field testing.

PNNL, a Department of Energy national laboratory, has demonstrated QPAS's ability to detect gaseous nerve agent surrogates. In one test, researchers used diisopropyl methyl phosphonate (DIMP), which is a chemical compound that's similar to sarin. QPAS detected DIMP at the sub-part-per-billion level in less than one minute.

Scientists' inability to follow the whereabouts of cells injected into the human body has long been a major drawback in developing effective medical therapies. Now, researchers at Johns Hopkins have developed a promising new technique for noninvasively tracking where living cells go after they are put into the body. The new technique, which uses genetically encoded cells producing a natural contrast that can be viewed using magnetic resonance imaging (MRI), appears much more effective than present methods used to detect injected biomaterials.

Described in the February edition of Nature Biotechnology, the method was developed by a team of researchers from Johns Hopkins' Russell H.

Laws in two states requiring disclosure of pharmaceutical company payments to physicians do not provide the public with easy access to payment information and are of limited quality when accessed, according to a study in the March 21 issue of JAMA.

Interactions between the pharmaceutical industry and health care professionals often involve payments, including cash, gift certificates, meals, textbooks or conference fees. In contrast to many other professions, medicine allows payments from a company to an individual who decides whether and how often to use products produced by the company.

According to the Centers for Disease Control (CDC), adolescents and young adults currently account for fifty percent of new HIV infections on an annual basis. As a result, ongoing research and information on HIV prevention has become a high priority for this age group. Now a new study reveals that helping adolescents manage their emotions may be just as important as providing them with information on the practical side of safe sex in order to prevent HIV and other sexually transmitted infections.

Researchers from the Bradley Hasbro Children's Research Center and the Warren Alpert Medical School of Brown University studied 222 adolescents between the ages of 13 and 18 with psychiatric disorders and found that feelings do matter when it comes to making decisions about safe sex.

Hurricanes Katrina and Rita focused the international spotlight on the vulnerability of the U.S. coastline. Fears that a "super-hurricane" could make a direct hit on a major city and cause even more staggering losses of life, land and economy triggered an outpouring of studies directed at every facet of this ferocious weather phenomenon. Now, an LSU professor takes us one step closer to predicting the future by drilling holes into the past.

Kam-biu Liu, George William Barineau III Professor in LSU's Department of Oceanography and Coastal Sciences, is the pioneer of a relatively new field of study called paleotempestology, or the study of prehistoric hurricanes.

Direct detection of base sequence in duplex nucleic acid has long been an unfulfilled objective. Ingeneus Research will publish "Heteropolymeric Triplex-Based Genomic Assay® to Detect Pathogens or Single-Nucleotide Polymorphisms in Human Genomic Samples" in the March 21st issue of the international, peer-reviewed, open access, online journal, PLoS ONE. In the article they present a wealth of data relating to the assay of pathogens in samples also containing human genomic duplex DNA and to the assay of SNPs present in human genomic samples. The assays are carried out homogeneously and in solution at room temperature. Reactions can be monitored after as little as five minutes.

Researchers have identified a novel gene mutation that causes X-linked mental retardation for which there was no previously known molecular diagnosis, according to an article to be published electronically on Tuesday, March 20, 2007 in The American Journal of Human Genetics.

Investigators F. Lucy Raymond (Cambridge Institute of Medical Research, University of Cambridge, Cambridge, UK) and Patrick S. Tarpey (Wellcome Trust Sanger Institute, Hixton, UK) describe the ZDHHC9 gene found in those with severe retardation as being mutated to the point of entirely losing function.

A small molecule derived from the spacer domain of the tumor-suppressor gene Rb2/p130 has demonstrated the ability to inhibit tumor growth in vivo and could be developed into an anti-cancer therapeutic, according to researchers at Temple University's Sbarro Institute for Cancer Research and Molecular Medicine.

The researchers reported their findings, "A small molecule based on the pRb2/p130 spacer domain leads to inhibition of cdk2 activity, cell cycle arrest and tumor growth reduction in vivo," in the March 22 issue of the journal Oncogene (http://www.nature.com/onc).